Your session is about to expire
← Back to Search
EMG Testing for Obstructive Sleep Apnea
N/A
Waitlist Available
Led By Perry Mansfield, MD
Research Sponsored by Powell Mansfield Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour
Awards & highlights
Study Summary
This is a pilot study to examine the diagnostic utility of a novel transmembrane surface sensor, and compare signals obtained with the transmembrane sensor to conventional needle EMG signals from healthy volunteers to those with documented neurologic pharyngeal muscle dysfunction (ALS and muscular dystrophy) and to those with severe OSA.
Eligible Conditions
- Obstructive Sleep Apnea
- Healthy Subjects
- Amyotrophic Lateral Sclerosis
- Muscular Dystrophy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 hour
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 hour
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proof of Diagnostic Consistency
Secondary outcome measures
Neuromuscular function in OSA Participants versus Healthy Participants
Trial Design
1Treatment groups
Experimental Treatment
Group I: EMG TestingExperimental Treatment1 Intervention
Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmenbrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transmembrane EMG Oropharynx Probe
2019
N/A
~50
Find a Location
Who is running the clinical trial?
Powell Mansfield Inc.Lead Sponsor
Perry Mansfield, MDPrincipal InvestigatorPerry Mansfield MD Inc.
Share this study with friends
Copy Link
Messenger